Teriflunomide

• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Not authorised
  2023-503631-18-00 Phase III 2 countries Sanofi-Aventis Research & Development
• DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Recruiting
  2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
• DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting
  2024-513475-41-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 Phase III 23 countries Sanofi-Aventis Recherche & Developpement
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended
  2024-514343-29-00 Phase III 16 countries Sanofi-Aventis Recherche & Developpement
• Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended
  2023-503190-38-00 Phase II 1 country Antwerp University Hospital
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509345-12-00 Phase III 13 countries Novartis Pharma AG
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509372-41-00 Phase III 15 countries Novartis Pharma AG
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended
  2022-502609-14-00 Phase III 7 countries F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended
  2022-502618-95-00 Phase III 7 countries F. Hoffmann-La Roche AG
• STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended
  2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
• Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended
  2023-507431-37-00 Phase III 4 countries Novartis Pharma AG

Showing 1–12 of 12 trials